Conference Call Schedules, Publication of Study Results, and Public Offer Pricing - Research Reports on Medivation, Keryx, Amicus, AGTC and Clovis
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, July 30, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Medivation, Inc. (NASDAQ: MDVN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Amicus Therapeutics, Inc. (NASDAQ: FOLD), Applied Genetic Technologies Corporation (NASDAQ: AGTC) and Clovis Oncology, Inc. (NASDAQ: CLVS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5255-100free.
Medivation, Inc. Research Reports
On July 24, 2014, Medivation, Inc. (Medivation) announced its plans to release its Q2 2014 financial results on August 7, 2014, after the close of the market. In conjunction with the earnings release, the Company will hold a conference call on August 7, 2014, at 4:30 p.m. ET to discuss the financial results as well as to provide general business update. Individuals may access the live audio webcast by visiting the Company's website. The full research reports on Medivation are available to download free of charge at:
http://www.analystsreview.com/Jul-30-2014/MDVN/report.pdf
Keryx Biopharmaceuticals Inc. Research Reports
On July 24, 2014, Keryx Biopharmaceuticals, Inc. (Keryx) announced that results from the long-term, randomized, active control Phase 3 study of Zerenex (ferric citrate) has been published in the Journal of the American Society of Nephrology (JASN). Zerenex is the Company's investigational oral ferric iron-based phosphate binder for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis. The results showed that Zerenex met the study's primary end-point demonstrating a highly statistically significant change in serum phosphorus versus placebo over the four-week Placebo Control Period. Ron Bentsur, CEO of Keryx, commented, "We are very pleased with the publication of the Phase 3 PERFECTED study results in a premier peer-reviewed nephrology journal and are encouraged by Zerenex's potential differentiated product profile." Mr. Bentsur added, "We thank the investigators and patients who participated in this study and look forward to potentially bringing Zerenex to market in the U.S." The Company's New Drug Application (NDA) for Zerenex is currently under review by the U.S. Food and Drug Administration (FDA). The full research reports on Keryx are available to download free of charge at:
http://www.analystsreview.com/Jul-30-2014/KERX/report.pdf
Amicus Therapeutics, Inc. Research Reports
On July 25, 2014, Amicus Therapeutics Inc.'s (Amicus) stock increased 4.46% to end the day at $4.45 compared to the previous day's closing price at $4.26. The Company's stock jumped 17.38% over the past five trading days, compared to the Nasdaq Composite which rose 0.39% during the same trading period. The full research reports on Amicus are available to download free of charge at:
http://www.analystsreview.com/Jul-30-2014/FOLD/report.pdf
Applied Genetic Technologies Corporation Research Reports
On July 24, 2014, Applied Genetic Technologies Corp. (AGTC) announced the pricing of its public offering of 2 million shares of its common stock at a price to the public of $15.00 per share. The Company has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares at the public offering price to cover possible over-allotments. The Company intends to use the net proceeds from the offering to fund preclinical investigation and Phase 1/2 trials of potential product candidates for treatment of wet AMD, to expand its manufacturing capabilities and create a pilot manufacturing group, to in-license, acquire or invest in complementary gene therapy, technologies, products or assets, and for working capital and other general corporate purposes. The full research reports on AGTC are available to download free of charge at:
http://www.analystsreview.com/Jul-30-2014/AGTC/report.pdf
Clovis Oncology, Inc. Research Reports
On July 21, 2014, Clovis Oncology Inc. (Clovis) announced that it is scheduled to release its Q2 2014 financial results on August 7, 2014, Thursday, after the close of the market. Following the earnings release, the Company's senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results. The conference call webcast can be accessed via the Company's website. The full research reports on Clovis are available to download free of charge at:
http://www.analystsreview.com/Jul-30-2014/CLVS/report.pdf
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article